A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer.

被引：0
|
作者：
Bjerregaard, Jon Kroll
Ladekarl, Morten
Jensen, Helle Anita
Vestermark, Lene Weber
Farr, Katherina Podlekareva
Pfeiffer, Per
机构：
[1] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark
[2] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark
[3] Odense Univ Hosp, DK-5000 Odense, Denmark
[4] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e15238
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15238
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer.
    Overman, Michael J.
    Eng, Cathy
    Kee, Bryan K.
    Fogelman, David R.
    Fark, Christine
    Hippert, Rick
    Holter, Scott
    Issa, Jean-Pierre
    Hamilton, Stanley R.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [42] Cetuximab plus capecitabine/irinotecan (XELIRI) versus cetuximab plus capecitabine/oxaliplatin (XELOX) as first line treatment for patients with metastatic colorectal cancer (CRC): A randomized trial of the AIO CRC study group
    Von Weikersthal, Ludwig Fischer
    Moosmann, Nicolas
    Vehling-Kaiser, U.
    Stauch, Martina
    Schlimok, G.
    Schulze, M.
    Walther, J.
    Weiss, J.
    Dietzfelbinger, H.
    Heinemann, Volker
    ANNALS OF ONCOLOGY, 2006, 17 : 115 - 115
  • [43] Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer.
    Ueno, Makoto
    Kobayashi, Satoshi
    Ohkawa, Shinichi
    Kameda, Ryo
    Andou, Tomoko
    Sugimori, Kazuya
    Miwa, Haruo
    Ko, Ryonho
    Tanaka, Katsuaki
    Taguri, Masataka
    Morita, Satoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
    Matsuda, Chu
    Kudo, Toshihiro
    Morimoto, Yoshihiro
    Kagawa, Yoshinori
    Tei, Mitsuyoshi
    Ide, Yoshihito
    Miyoshi, Norikatsu
    Takahashi, Hidekazu
    Uemura, Mamoru
    Takemasa, Ichiro
    Satoh, Taroh
    Mizushima, Tsunekazu
    Murata, Kohei
    Doki, Yuichiro
    Eguchi, Hidetoshi
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2023, 7 (01): : 81 - 90
  • [45] A Phase I Study of Neoadjuvant Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) in Patients with Locally Advanced Rectal Cancer
    Kudo, Toshihiro
    Takemasa, Ichiro
    Hata, Tsuyoshi
    Sakai, Daisuke
    Takahashi, Hidekazu
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Satoh, Taroh
    Mizushima, Tsunekazu
    Mori, Masaki
    Doki, Yuichiro
    ONCOLOGY, 2019, 97 (04) : 211 - 216
  • [46] A Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer
    Wong, Nan Soon
    Fernando, Nishan H.
    Nixon, Andrew B.
    Cushman, Stephanie
    Aklilu, Mebea
    Bendell, Johanna C.
    Morse, Michael A.
    Blobe, Gerard C.
    Ashton, Jill
    Pang, Herbert
    Hurwitz, Herbert I.
    ANTICANCER RESEARCH, 2011, 31 (01) : 255 - 261
  • [47] Phase I and II studied of intravenous Rexin-G as monotherapy for stage IVb gemcitabine-resistant pancreatic cancer
    Bruckner, W.
    Chawla, S. P.
    Chua, C. S.
    Quon, D. V.
    Fernandez, L.
    Saralou, A.
    Fisher, M.
    Gordon, E. M.
    Hall, F. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Cetuximab plus capecitabine plus irinotecan (CCI) versus cetuximab plus capecitabine plus oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group.
    Heinemann, V.
    Von Weikersthal, L. Fischer
    Moosmann, N.
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Walther, J.
    Weiss, J.
    Dietzfelbinger, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 158S - 158S
  • [49] REVERCE: Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin, and Irinotecan
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 12 - 14
  • [50] Phase I study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
    Machiels, J. P.
    Sempoux, C.
    Scalliet, P.
    Coche, J. C.
    Coster, B.
    Canon, J. L.
    Kerger, J.
    Van Cutsem, E.
    Peeters, M.
    Haustermans, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 159S - 159S
12345